Neurocrine Biosciences, Inc. NBIX
Set alert
As of Nov 3, 1:34 PM ET
- YTD
- +18.72%
- 1 year
- +18.61%
- Open
- 159.00
- Prev close
- 145.35
- Mkt cap
- 17.12B
- Vol
- 2.35M
- Avg vol
- 1.25M
- EPS
- 6.74
- P/E
- 24.98
- Div yield
- 0.00%
More statistics
- Low
- 157.91
- High
- 169.53
- Forward P/E
- 12.14
- Beta
- 0.33
- Short ratio
- 4.41
- Inst. own
- 104.46%
- Dividend
- 0.00
- Ex-div date
- Dec 28, 1995
- Earnings
- Feb 10, 2027
- 50-d avg
- 146.63
- 200-d avg
- 147.38
- 1y target
- 206.22
1m chart
Built from the cached one-day intraday bars.
Signals (76)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 1:34 PM | 2 minutes ago |
| SMA: Bullish | Nov 3, 1:34 PM | 2 minutes ago |
| SMA: Bearish | Nov 3, 1:29 PM | 7 minutes ago |
| SMA: Bearish | Nov 3, 1:24 PM | 12 minutes ago |
| MACD: Sell Signal | Nov 3, 1:24 PM | 12 minutes ago |
| RSI: Overbought | Nov 3, 1:14 PM | 22 minutes ago |
| RSI: Overbought | Nov 3, 1:09 PM | 27 minutes ago |
| RSI: Overbought | Nov 3, 1:07 PM | 29 minutes ago |
| SMA: Bullish | Nov 3, 1:01 PM | 35 minutes ago |
| SMA: Bullish | Nov 3, 12:56 PM | 40 minutes ago |
| SMA: Bearish | Nov 3, 12:53 PM | 43 minutes ago |
| SMA: Bullish | Nov 3, 12:52 PM | 44 minutes ago |
| SMA: Bearish | Nov 3, 12:51 PM | 45 minutes ago |
| SMA: Bullish | Nov 3, 12:44 PM | 52 minutes ago |
| SMA: Bullish | Nov 3, 12:40 PM | 56 minutes ago |
| SMA: Bearish | Nov 3, 12:39 PM | 57 minutes ago |
| MACD: Buy Signal | Nov 3, 12:39 PM | 57 minutes ago |
| SMA: Bullish | Nov 3, 12:37 PM | 59 minutes ago |
| RSI: Oversold | Nov 3, 12:35 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 12:31 PM | 1 hour ago |
Newest 20 of 76.
Key statistics
- Market cap
- 14.77B
- Enterprise value
- 14.92B
- Trailing P/E
- 21.31
- Forward P/E
- 12.14
- PEG ratio
- 0.30
- Price / sales
- 4.38
- Price / book
- 4.00
- EPS (TTM)
- 6.82
- Beta
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.91%
- Revenue (TTM)
- 3.37B
- Revenue growth
- 39.50%
- Free cash flow
- 638.24M
- Total cash
- 389.80M
- Total debt
- 461.60M
- Return on equity
- 22.09%
- Shares outstanding
- 101.65M
- Short % of float
- 8.24%
- 50-day average
- 146.63
- 200-day average
- 147.38
Analyst view
Consensus: strong buy
- Target (low)
- 150.00
- Target (mean)
- 206.22
- Target (high)
- 253.00
- Strong buy4
- Buy21
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate 2.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | 1.92 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 1.91 | 3.29 | +1.38 | +72.25% |
| Jul 30, 2026 | Jun 30, 2026 | 1.85 | 2.85 | +1.00 | +54.05% |
| May 5, 2026 | Mar 31, 2026 | 1.22 | 1.91 | +0.69 | +56.56% |
| Feb 11, 2026 | Dec 31, 2025 | 1.80 | 1.88 | +0.08 | +4.44% |
| Oct 28, 2025 | Sep 30, 2025 | 1.58 | 2.04 | +0.46 | +29.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Sep 29, 2026 | UBS | main | Buy | Buy |
| Sep 11, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 8, 2026 | RBC Capital | reit | Outperform | Outperform |
| Sep 3, 2026 | Citigroup | main | Buy | Buy |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- neurocrine.com
News
- Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185
- Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
- Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday
- RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190
- Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
- Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215
- Neurocrine Biosciences Q3 Earnings Call Highlights
- Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Your note
Sign in to keep a note on NBIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNETHY MATTHEW C | Chief Financial Officer | Sale | Sep 13, 2026 | 42,808 |
| BENEVICH ERIC S. | Officer | Stock Award(Grant) | Sep 10, 2026 | 67,297 |
| COOKE JULIE SMITH | Officer | Stock Award(Grant) | Sep 10, 2026 | 24,025 |
| GANO KYLE W | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2026 | 154,728 |
| GORMAN KEVIN CHARLES | Director | Stock Award(Grant) | Sep 10, 2026 | 517,797 |
| LIPPOLDT DARIN M | Officer | Stock Award(Grant) | Sep 10, 2026 | 56,793 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.49% | 13,711,607 | 1.99B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.29% | 6,398,674 | 930.05M | Jun 29, 2026 |
| Dodge & Cox Inc. | 5.49% | 5,584,707 | 811.74M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.89% | 4,974,083 | 722.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 4,545,339 | 660.67M | Jun 29, 2026 |
| State Street Corporation | 4.31% | 4,385,598 | 637.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.90% | 3,964,000 | 576.17M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 3,620,760 | 526.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 3,193,267 | 464.14M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 2,304,996 | 335.03M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% | 1,358,475 | 197.45M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 1,329,829 | 193.29M | Jun 29, 2026 |